Source-grounded facts extracted from Amphastar Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Amphastar Pharmaceuticals, Inc. shareholders approved Advisory vote on frequency of future stockholder advisory votes on named executive officer compensation.
“4. Advisory Vote on the Frequency of Future Stockholder Advisory Votes on Named Executive Officer Compensation 1 Year 2 Years 3 Years Abstained Broker Non-votes 33,816,071 12,329 1,624,016 24,576 4,439,978”
Amphastar Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers.
“3. Advisory Vote on the Compensation of our Named Executive Officers For Against Abstained Broker Non-votes 32,585,908 2,779,281 111,803 4,439,978”
Amphastar Pharmaceuticals, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm.
“2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-votes 39,179,786 684,828 52,356 N/A”
Amphastar Pharmaceuticals, Inc. shareholders approved Election of three Class I directors.
“1. Election of Directors Nominee For Against Abstained Broker Non-votes David Gaugh 35,242,863 209,084 25,045 4,439,978 William J. Peters 23,652,131 11,785,772 39,089 4,439,978 Jacob Liawatidewi 23,224,791 12,212,988 39,213 4,439,978”
Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2026 results: net income Adjusted non-GAAP net income of $19.5 million, EPS $0.42 per share.
“of $171.2 million for the three months ended March 31, 2026 - GAAP net income of $6.4 million, or $0.14 per share, for the first quarter - Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter - Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA – May 7, 2026 – Amphastar Pharmaceuticals,”
Amphastar Pharmaceuticals, Inc. amended Contract Research Amendment with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at approximately $0.6 million (effective 2026-03-03).
“On March 3, 2026 (the “Effective Date”), Amphastar Pharmaceuticals, Inc (“Amphastar” or, the “Company”) and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”) entered into an amendment (the “Contract Research Amendment”) to the Contract Research Agreement (the “Contract Research Agreement”), originally entered into on September 15, 2025, as previously reported by the Company on a Current Report on Form 8-K filed on September 18, 2025.”
Amphastar Pharmaceuticals, Inc. entered into Supply Agreement with Nanjing Letop Biotechnology Co., Ltd. (effective 2026-03-03).
“On March 3, 2026, (the “Effective Date”), Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), the Chinese subsidiary of Amphastar Pharmaceuticals, Inc. (“Amphastar” or, the “Company”), entered into a supply agreement (the “Supply Agreement”) with Nanjing Letop Biotechnology Co., Ltd. (“Letop”).”
Amphastar Pharmaceuticals, Inc. amended Manufacturing Amendment with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at Change in value not determinable; expands territory globally except US and Canada for Lidocaine and (effective 2026-01-06).
“On January 6, 2026, Amphastar Nanjing Pharmaceuticals, Inc., the Chinese subsidiary of Amphastar and Hanxin entered into an amendment to the Manufacturing Agreement (the “Manufacturing Amendment”), originally entered into on April 19, 2022, as previously reported by the Company on a Current Report on Form 8-K filed on April 22, 2022.”
Amphastar Pharmaceuticals, Inc. amended Distribution Amendment with Hong Kong Genreach Limited valued at Change in value not determinable; expands region with additions of Middle East and Southeast Asian c (effective 2026-01-06).
“On January 6, 2026, Armstrong Pharmaceuticals, Inc. a wholly-owned subsidiary of the Amphastar and Hong Kong Genreach Limited (“Genreach”) a wholly-owned subsidiary of Hanxin entered into an amendment to the Distribution Agreement (the “Distribution Amendment”), originally entered into on August 28, 2024, as previously reported by the Company on a Current Report on Form 8-K filed on August 30, 2024 (the “Distribution Agreement”).”
Amphastar Pharmaceuticals, Inc. entered into License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at Amphastar made an upfront payment of $2 million; development milestone payments up to $14 million; s (effective 2026-01-06).
“On January 6, 2026, Amphastar Pharmaceuticals, Inc (“Amphastar” or, the “Company”), and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”), entered into a License Agreement (“License Agreement”) pursuant to which Hanxin is granting an exclusive license to certain intellectual property controlled by Hanxin to develop, make, use and commercialize products incorporating or comprising of corticotropin compound (“Licensed Product”) in the United States and Canada (the “Territory”).”
Amphastar Pharmaceuticals, Inc.: Approved amendment to Bylaws to clarify exclusive forum selection for certain legal actions (effective 2025-06-02).
“the board of directors of the Company approved an amendment to the amended and restated bylaws of the Company (the “Bylaws” and such amendment, the "Bylaws Amendment”) clarifying that unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court in Delaware or the United States District Court for the District of Delaware) and any appellate court therefrom will be the sole and exclusive forum”
Amphastar Pharmaceuticals, Inc.: Approved amendment to Charter to remove forum selection provision (effective 2025-06-02).
“and (ii) to remove the forum selection provision (the “Forum Selection Amendment,” and together with the Exculpation Amendment, the “Charter Amendments”).”
Amphastar Pharmaceuticals, Inc.: Approved amendment to Charter to include officer exculpation provisions under Delaware law (effective 2025-06-02).
“the stockholders of the Company voted on and approved amendments to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) (i) to reflect Delaware law provisions regarding officer exculpation (the “Exculpation Amendment”);”
Amphastar Pharmaceuticals, Inc. reported the three months ended March 31, 2024 results: revenue $171.8 million, net income $43.2 million, EPS $0.81 per share.
“Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2024. First Quarter Highlights ● Net revenues of $171.8 million for the first quarter ● GAAP net income of $43.2 million, or $0.81 per share, for the first quarter”
Amphastar Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: revenue $180.6 million, net income $49.2 million, or $0.91 per share, EPS $0.91 per share.
“in such a filing. --- EX-99.1 (EX-99.1) --- Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 23 Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 RANCHO CUCAMONGA, CA – November 8, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today”
Amphastar Pharmaceuticals, Inc. incurred senior notes of up to an additional $45.0 million aggregate principal amount of Notes.
“Initial Purchasers an option to purchase, for settlement during a 13-day period beginning on, and including, the date on which the Notes were first issued, up to an additional $45.0 million aggregate principal amount of Notes on the same terms and conditions. The Initial Purchasers exercised their option in full on September 14, 2023, bringing the total aggregate”
Amphastar Pharmaceuticals, Inc. incurred senior notes of $300.0 million aggregate principal amount with Jefferies LLC, J.P. Morgan Securities LLC, Wells Fargo Securities, LLC and BofA Securities, Inc., as representatives of the several initial purchasers at 2.00% per annum maturing March 15, 2029.
“Morgan Securities LLC, Wells Fargo Securities, LLC and BofA Securities, Inc., as representatives of the several initial purchasers (the “Initial Purchasers”), to issue and sell $300.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2029 (the “Notes”). In addition, the Company granted the Initial Purchasers an option to purchase, for settlement”
Amphastar Pharmaceuticals, Inc. entered into Purchase Agreement with Jefferies LLC, J.P. Morgan Securities LLC, Wells Fargo Securities, LLC and BofA Securities, Inc., as representatives of the several initial purchasers valued at $300.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2029 (effective 2023-09-12).
“On September 12, 2023, Amphastar Pharmaceuticals, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Jefferies LLC, J.P. Morgan Securities LLC, Wells Fargo Securities, LLC and BofA Securities, Inc., as representatives of the several initial purchasers (the “Initial Purchasers”), to issue and sell $300.0 million aggregate principal amount of 2.00% Convertible Senior Notes due 2029 (the “Notes”).”
Amphastar Pharmaceuticals, Inc. completed an acquisition involving Eli Lilly and Company for $500 million in cash (closed 2023-06-30).
“ The proceeds of the Credit Facilities were used to finance the acquisition of BAQSIMI ® glucagon nasal powder (“BAQSIMI ® ”) and related assets (the “Transferred Assets”) from Eli Lilly and Company, an Indiana corporation (“Lilly”), to refinance certain of Amphastar’s and its subsidiaries’ existing third-party indebtedness, and to pay fees and expenses incurred in connection with each of the foregoing.”
Amphastar Pharmaceuticals, Inc. incurred term loan of $500.0 million with Wells Fargo Bank, National Association at base rate ... plus an applicable margin of 1.25%, or ... adjusted Term SOFR rate maturing June 30, 2028.
“The Credit Agreement also provides for the incurrence by Amphastar of a senior secured term loan in an aggregate principal amount of $500.0 million (the "Term Loan", and together with the Revolving Credit Facility, the "Credit Facilities"). The Term Loan matures on the Maturity Date. The Term Loan was fully funded on the Closing Date.”
Amphastar Pharmaceuticals, Inc. incurred credit facility of $200.0 million with Wells Fargo Bank, National Association at base rate ... plus an applicable margin of 1.25%, or ... adjusted Term SOFR rate maturing June 30, 2028.
“The Credit Agreement provides for a senior secured revolving credit facility (the "Revolving Credit Facility") in an aggregate principal amount of $200.0 million”
Amphastar Pharmaceuticals, Inc. entered into Credit Agreement with Wells Fargo Bank, National Association, as Administrative Agent, Swing Line Lender and L/C Issuer, and the lenders party thereto valued at $700.0 million ($200.0 million Revolving Credit Facility and $500.0 million Term Loan) (effective 2023-06-30).
“On June 30, 2023 (the “Closing Date”), Amphastar Pharmaceuticals, Inc., a Delaware corporation (“Amphastar” or the “Company”), entered into a Credit Agreement (the “Credit Agreement”) by and among the Company, certain subsidiaries of the Company party thereto, as guarantors, the lenders party thereto, and Wells Fargo Bank, National Association, as Administrative Agent (in such capacity, “Agent”), Swing Line Lender and L/C Issuer.”
Amphastar Pharmaceuticals, Inc. shareholders approved Approve, on an advisory basis, the compensation of our named executive officers at the 2023-06-05 meeting.
“To approve, on an advisory basis, the compensation of our named executive officers.”
Amphastar Pharmaceuticals, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-05 meeting.
“The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Amphastar Pharmaceuticals, Inc. shareholders approved Election of three Class I directors to serve until the 2026 annual meeting at the 2023-06-05 meeting.
“On June 5, 2023, the Company held its Annual Meeting virtually via a live webcast.”
Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: revenue 140.0 million, net income 26.0 million, EPS 0.50.
“Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023”
Amphastar Pharmaceuticals, Inc. entered into Debt Commitment Letter with Wells Fargo Bank, Capital One, JPMorgan Chase Bank, East West Bank, Cathay Bank, Fifth Third Bank, CIBC Bank USA valued at senior secured term loan facility in aggregate principal amount of $500 million and senior secured r (effective 2023-04-21).
“In connection with the Purchase Agreement, Amphastar entered into a debt commitment letter (the “Commitment Letter”), dated as of April 21, 2023, with Wells Fargo Bank, National Association (“Wells Fargo Bank”), Capital One, National Association (“Capital One”), JPMorgan Chase Bank, N.A. (together with any of its affiliates through which it may be acting, “JPMorgan”), East West Bank (“East West Bank”), Cathay Bank (“Cathay”), Fifth Third Bank, National Association (“Fifth Third”), and CIBC Bank USA (“CIBC” and, collectively with Wells Fargo Bank, Capital One, JPMorgan, East West Bank, Cathay and Fifth Third, the “Commitment Parties”) pursuant to which the Commitment Parties have committed to provide a senior secured term loan facility in an aggregate principal amount of $500 million and a senior secured revolving credit facility in an aggregate principal amount of $150 million (collectively, the “Debt Financing”). The Debt Financing is available (i) to finance the Acquisition, (ii) to”
Amphastar Pharmaceuticals, Inc. entered into Asset Purchase Agreement with Eli Lilly and Company valued at purchase price of $500 million in cash payable at the closing, plus a $125 million guaranteed paymen (effective 2023-04-21).
“On April 21, 2023, Amphastar Pharmaceuticals, Inc., a Delaware corporation (“Amphastar” or the “Company”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Eli Lilly and Company, an Indiana corporation (“Lilly”), pursuant to which Amphastar’s wholly owned subsidiary, Amphastar Medication Co., LLC, a Delaware limited liability company (“Amphastar Medication”), has agreed to acquire Lilly’s BAQSIMI ® glucagon nasal powder (“BAQSIMI ® ”) and related assets (the “Transferred Assets”) and assume certain liabilities (the “Assumed Liabilities”) for a purchase price of $500 million in cash payable at the closing of the transaction (the “Acquisition”). In addition, Amphastar will pay Lilly a $125 million guaranteed payment on the first anniversary after the consummation of the transactions contemplated by the Purchase Agreement (the “Closing”). Amphastar may also be required to pay additional contingent consideration of up to $450 million to Lilly based on the achievemen”
Amphastar Pharmaceuticals, Inc. amended Contract Research Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at not exceed approximately $0.5 million (effective 2023-03-08).
“On March 8, 2023, Amphastar Pharmaceuticals, Inc. (together with its subsidiaries, the “Company”) and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”) entered into an Amendment to that certain Contract Research Agreement by and between the Company and Hanxin, dated July 5, 2022 (the “Amendment”).”
Amphastar Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2022 results: revenue $499.0 million, net income $91.4 million, EPS $1.74 per share.
“Net revenues of $499.0 million for the fiscal year ● GAAP net income of $91.4 million, or $1.74 per share, for the fiscal year ● Adjusted non-GAAP net income of $103.2 million, or $1.97 per share, for the fiscal year”
Amphastar Pharmaceuticals, Inc. reported the three months ended December 31, 2022 results: revenue $135.0 million, net income $33.9 million, EPS $0.66 per share.
“Net revenues of $135.0 million for the fourth quarter ● GAAP net income of $33.9 million, or $0.66 per share, for the fourth quarter ● Adjusted non-GAAP net income of $37.6 million, or $0.73 per share, for the fourth quarter”
Amphastar Pharmaceuticals, Inc.: Approved Amended and Restated Bylaws revising director nomination and stockholder proposal procedures, stockholder meeting procedures, director/committee/officer provisions, and adding a forum selection clause (effective 2023-02-23).
“On February 23, 2023, the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”).”
Amphastar Pharmaceuticals, Inc. entered into Agreement with Nanjing Letop Biotechnology Co., Ltd. valued at approximately $1.5 million (effective 2022-11-15).
“On November 15, 2022 (the “Effective Date”) Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), a wholly owned subsidiary of Amphastar Pharmaceuticals, Inc. (the “Company”), entered into a supply agreement (the “Agreement”) with Nanjing Letop Biotechnology Co., Ltd. (“Letop”).”
Amphastar Pharmaceuticals, Inc. reported three months ended September 30, 2022 results: revenue $120.1 million, net income $15.9 million, EPS $0.30 per share.
“in such a filing. --- EX-99.1 (EX-99.1) --- Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 22 Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022 RANCHO CUCAMONGA, CA – November 7, 2022 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today”
Jacob Liawatidewi was appointed as Class I Director at Amphastar Pharmaceuticals, Inc..
“appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors”
William J. Peters was appointed as Class I Director at Amphastar Pharmaceuticals, Inc..
“appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors”
David Maris resigned as Director at Amphastar Pharmaceuticals, Inc..
“On August 19, 2021, David Maris tendered his resignation to the Board of Directors (the “ Board ”) of Amphastar Pharmaceuticals, Inc. (the “ Company ”) effective immediately.”
Richard Koo retired as Director at Amphastar Pharmaceuticals, Inc..
“On August 5, 2021, Richard Koo announced his retirement from the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”) effective as of September 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.